Enteral supplement enriched with glutamine, fiber, and oligosaccharide attenuates experimental colitis in mice

Nutrition

Volumn 29, Issue 3, 2013, Pages 549-555

  Joo, Erina ^a   Yamane, Shunsuke ^a   Hamasaki, Akihiro ^a   Harada, Norio ^a   Matsunaga, Tetsuro ^a   Muraoka, Atsushi ^a   Suzuki, Kazuyo ^a   Nasteska, Daniela ^a   Fukushima, Toru ^a   Hayashi, Tatsuya ^a   Tsuji, Hidemi ^a   Shide, Kenichiro ^a   Tsuda, Kinsuke ^a   Inagaki, Nobuya ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Dextran sulfate sodium; GFO; Glucagon like peptide; Interleukin 1 ; Ulcerative colitis

Indexed keywords

DEXTRAN SULFATE; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; GLUTAMINE; INSULIN; INTERLEUKIN 1BETA; MESSENGER RNA; OLIGOSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENUATION; COLON MUCOSA; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE ACTIVITY; ENTERIC FEEDING; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; INTERLEUKIN 1BETA GENE; MALE; MOUSE; NONHUMAN; NUTRIENT CONTENT; NUTRIENT MANAGEMENT; NUTRITIONAL STATUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; THERAPY EFFECT; TISSUE STRUCTURE; TUMOR NECROSIS FACTOR ALPHA GENE; ULCERATIVE COLITIS; WEIGHT CHANGE; WEIGHT REDUCTION;

ANIMALS; COLITIS, ULCERATIVE; COLON; CYTOKINES; DEXTRAN SULFATE; DIETARY FIBER; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; ENTERAL NUTRITION; GLUTAMINE; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; OLIGOSACCHARIDES; RNA, MESSENGER;

MUS;

EID: 84873567876     PISSN: 08999007     EISSN: 18731244     Source Type: Journal    
DOI: 10.1016/j.nut.2012.09.007     Document Type: Article

References (43)

1. Eaden J.A., Abrams K.R., Mayberry J.F. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001, 48:526-535.
2. Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 2006, 73:67-76.
3. Faubion W.A., Loftus E.V., Harmsen W.S., Zinsmeister A.R., Sandborn W.J. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 2001, 121:255-260.
4. Andoh A., Fujiyama Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J Gastroenterol 2006, 12:4452-4460.
5. Kanauchi O., Mitsuyama K., Araki Y., Andoh A. Modification of intestinal flora in the treatment of inflammatory bowel disease. Curr Pharm Des 2003, 9:333-346.
6. Sartor R.B. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2006, 3:390-407.
7. Videla S., Vilaseca J., Antolin M., Garcia-Lafuente A., Guarner F., Crespo E., et al. Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat. Am J Gastroenterol 2001, 96:1486-1493.
8. Moreau N.M., Martin L.J., Toquet C.S., Laboisse C.L., Nguyen P.G., Siliart B.S., et al. Restoration of the integrity of rat caeco-colonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr 2003, 90:75-85.
9. Rumi G., Tsubouchi R., Okayama M., Kato S., Mozsik G., Takeuchi K. Protective effect of lactulose on dextran sulfate sodium-induced colonic inflammation in rats. Dig Dis Sci 2004, 49:1466-1472.
10. Hoentjen F., Welling G.W., Harmsen H.J., Zhang X., Snart J., Tannock G.W., et al. Reduction of colitis by prebiotics in HLA-B27 transgenic rats is associated with microflora changes and immunomodulation. Inflamm Bowel Dis 2005, 11:977-985.
11. Lara-Villoslada F., Debras E., Nieto A., Concha A., Galvez J., Lopez-Huertas E., et al. Oligosaccharides isolated from goat milk reduce intestinal inflammation in a rat model of dextran sodium sulfate-induced colitis. Clin Nutr 2006, 25:477-488.
12. Lindsay J.O., Whelan K., Stagg A.J., Gobin P., Al-Hassi H.O., Rayment N., et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006, 55:348-355.
13. Wang W.W., Qiao S.Y., Li D.F. Amino acids and gut function. Amino Acids 2009, 37:105-110.
14. Ameho C.K., Adjei A.A., Harrison E.K., Takeshita K., Morioka T., Arakaki Y., et al. Prophylactic effect of dietary glutamine supplementation on interleukin 8 and tumour necrosis factor alpha production in trinitrobenzene sulphonic acid induced colitis. Gut 1997, 41:487-493.
15. Giris M., Erbil Y., Dogru-Abbasoglu S., Yanik B.T., Alis H., Olgac V., et al. The effect of heme oxygenase-1 induction by glutamine on TNBS-induced colitis. The effect of glutamine on TNBS colitis. Int J Colorectal Dis 2007, 22:591-599.
16. Fillmann H., Kretzmann N.A., San-Miguel B., Llesuy S., Marroni N., Gonzalez-Gallego J., et al. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007, 236:217-226.
17. Hubert-Buron A., Leblond J., Jacquot A., Ducrotte P., Dechelotte P., Coeffier M. Glutamine pretreatment reduces IL-8 production in human intestinal epithelial cells by limiting IkappaBalpha ubiquitination. J Nutr 2006, 136:1461-1465.
18. Coeffier M., Marion R., Ducrotte P., Dechelotte P. Modulating effect of glutamine on IL-1beta-induced cytokine production by human gut. Clin Nutr 2003, 22:407-413.
19. Fukata M., Michelsen K.S., Eri R., Thomas L.S., Hu B., Lukasek K., et al. Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol 2005, 288:G1055-G1065.
20. Cooper H.S., Murthy S.N., Shah R.S., Sedergran D.J. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993, 69:238-249.
21. Okayasu I., Hatakeyama S., Yamada M., Ohkusa T., Inagaki Y., Nakaya R. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 1990, 98:694-702.
22. Peng X.D., Wu X.H., Chen L.J., Wang Z.L., Hu X.H., Song L.F., et al. Inhibition of phosphoinositide 3-kinase ameliorates dextran sodium sulfate-induced colitis in mice. J Pharmacol Exp Ther 2010, 332:46-56.
23. Culling C.F., Reid P.E., Dunn W.L. A histochemical comparison of the O-acylated sialic acids of the epithelial mucins in ulcerative colitis, Crohn's disease, and normal controls. J Clin Pathol 1979, 32:1272-1277.
24. Azuma H., Mishima S., Oda J., Homma H., Sasaki H., Hisamura M., et al. Enteral supplementation enriched with glutamine, fiber, and oligosaccharide prevents gut translocation in a bacterial overgrowth model. J Trauma 2009, 66:110-114.
25. Andoh A., Tsujikawa T., Fujiyama Y. Role of dietary fiber and short-chain fatty acids in the colon. Curr Pharm Des 2003, 9:347-358.
26. Clausen M.R., Mortensen P.B. Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis. Gut 1995, 37:684-689.
27. Kripke S.A., Fox A.D., Berman J.M., Settle R.G., Rombeau J.L. Stimulation of intestinal mucosal growth with intracolonic infusion of short-chain fatty acids. JPEN J Parenter Enteral Nutr 1989, 13:109-116.
28. Bartholome A.L., Albin D.M., Baker D.H., Holst J.J., Tappenden K.A. Supplementation of total parenteral nutrition with butyrate acutely increases structural aspects of intestinal adaptation after an 80% jejunoileal resection in neonatal piglets. JPEN J Parenter Enteral Nutr 2004, 28:210-222.
29. Galvez J., Rodriguez-Cabezas M.E., Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res 2005, 49:601-608.
30. Scheppach W. Treatment of distal ulcerative colitis with short-chain fatty acid enemas. A placebo-controlled trial. German-Austrian SCFA Study Group. Dig Dis Sci 1996, 41:2254-2259.
31. Baskerville A., Hambleton P., Benbough J.E. Pathological features of glutaminase toxicity. Br J Exp Pathol 1980, 61:132-138.
32. Chen K., Okuma T., Okamura K., Torigoe Y., Miyauchi Y. Glutamine-supplemented parenteral nutrition improves gut mucosa integrity and function in endotoxemic rats. JPEN J Parenter Enteral Nutr 1994, 18:167-171.
33. Reinecker H.C., Steffen M., Witthoeft T., Pflueger I., Schreiber S., MacDermott R.P., et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993, 94:174-181.
34. Murata Y., Ishiguro Y., Itoh J., Munakata A., Yoshida Y. The role of proinflammatory and immunoregulatory cytokines in the pathogenesis of ulcerative colitis. J Gastroenterol 1995, 30:56-60.
35. Holst J.J. Enteroglucagon. Annu Rev Physiol 1997, 59:257-271.
36. Drucker D.J., Erlich P., Asa S.L., Brubaker P.L. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A 1996, 93:7911-7916.
37. Brubaker P.L., Izzo A., Hill M., Drucker D.J. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab 1997, 272:E1050-E1058.
38. Guan X., Karpen H.E., Stephens J., Bukowski J.T., Niu S., Zhang G., et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology 2006, 130:150-164.
39. Yusta B., Boushey R.P., Drucker D.J. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 2000, 275:35345-35352.
40. Drucker D.J., Yusta B., Boushey R.P., DeForest L., Brubaker P.L. Human [Gly2] GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol Gastrointest Liver Physiol 1999, 276:G79-G91.
41. Thulesen J., Hartmann B., Nielsen C., Holst J.J., Poulsen S.S. Diabetic intestinal growth adaptation and glucagon-like peptide 2 in the rat: effects of dietary fibre. Gut 1999, 45:672-678.
42. Reimann F., Williams L., da Silva Xavier G., Rutter G.A., Gribble F.M. Glutamine potently stimulates glucagon-like peptide-1 secretion from GLUTag cells. Diabetologia 2004, 47:1592-1601.
43. Greenfield J.R., Farooqi I.S., Keogh J.M., Henning E., Habib A.M., Blackwood A., et al. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. Am J Clin Nutr 2009, 89:106-113.